Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibrexafungerp + pravastatin
- Development stage
- Unknown
- Lead developer
- Scynexis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of two drugs: - **Ibrexafungerp** (also known as SCY-078 or MK-3118) is a first-in-class, orally bioavailable triterpenoid antifungal agent that inhibits glucan synthase. It has broad-spectrum activity against Candida species (including multidrug-resistant strains such as C. auris), Aspergillus species, and Pneumocystis spp. Ibrexafungerp acts by inhibiting the synthesis of β-(1,3)-D-glucan in the fungal cell wall, leading to cell lysis and death. It is developed primarily for invasive fungal infections and vulvovaginal candidiasis[2][4][5][6]. - **Pravastatin** (PRA) is an HMG-CoA reductase inhibitor ("statin") used to lower cholesterol levels and prevent cardiovascular disease. The combination "SCY-078 + PRA" refers specifically to clinical pharmacokinetic studies evaluating potential drug-drug interactions between oral ibrexafungerp and pravastatin in healthy subjects[8]. There are no indications this combination is marketed as a fixed-dose product; it has been studied for interaction purposes only.
- Brand names
- BrexafemmePravachol
- Other names
- ibrexafungerp + pravastatin sodium
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)SLCO1B3 (Organic anion transporting polypeptide 1B3)FKS (1,3-beta-D-glucan synthase component FKS1)
Beyond the preview
Go deeper on ibrexafungerp + pravastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibrexafungerp + pravastatin.